Perspective · 10 Sep 2026
Conference abstractPublished 14 Jun 2018
Heterodimeric Fc-fused IL12 elicits antitumor effects by generating memory CD8+ T cells
Ajou University, South Korea
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Interleukin-12 (IL12) (p35/p40 complex) is a heterodimeric cytokine with potent anti-tumor activity. However, its short serum half-life and high dose-related toxicities limit its clinical efficacy. Methodology & Theoretical Orientation: In this study, we exploited heterodimeric Fc technology to develop mono-mIL12- Fc, which presents mIL12 in the naturally occurring heterodimeric form with an Fc-mediated extended serum half-life. We constructed heterodimeric Ig Fc-fused IL12 in the naturally occurring heterodimeric form of IL12, termed mono-mIL12-Fc, in which the p35 and p40 subunits were fused to the N-terminus of two different Fc variants, respectively. We also generated Fc-fused bivalent IL12 with two IL12 units (bi-mIL12-Fc) by fusion of scIL12 (p40-linker-p35) to the N-terminus of wild-type Fc as a control. Findings: Mono-mIL12-Fc exhibited a much longer plasma half-life than recombinant mIL12, enabling twice-weekly systemic injections to remove established tumors in syngeneic mouse models. Mono-mIL12-Fc was more potent than wild-type Fc-based bivalent-binding IL12-Fc (bi-mIL12-Fc) for eradicating large established immunogenic tumors without noticeable toxicities by enhancing interferon-gamma production and the proliferation of immune effector cells in tumors. More importantly, monomIL12- Fc triggered weaker IL12 signaling than bi-mIL12-Fc, favoring the generation of functional and protective memory CD8+ T cells. Notably, our study illustrates that mono-mIL12-Fc triggers modest pSTAT4 activation and T-bet expression in effector CD8+ T cells, resulting in a switch from T-bet to Eomes activation for the differentiation into MPECs and eventually long-lived memory CD8+ T cells. However, the strong IL12 signaling mediated by bi-mIL12-Fc drives effector CD8+ T cells into terminally differentiated SLECs, thereby excluding the development of MPECs. Conclusion & Significance: Our results demonstrate that heterodimeric-Fc-fused IL12 is a suitable format for augmenting adaptive CD8+ T cell immune responses, providing a practical alternative to the systemic administration of IL12 for anti-tumor therapy.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Jung-Eun Kim”
- BylineArticles whose byline prints “Yong-Sung Kim”
- BylineArticles whose byline prints “Keunok Jung”
